#MapLight_Therapeutics
LightNews LightNews
newsen.bsky.social
Investors of MapLight Therapeutics Face Fraud Investigation Opportunities with SBS Law#United_States#Los_Angeles#MapLight_Therapeutics#stock_investigation#SBS_Law
Investors of MapLight Therapeutics Face Fraud Investigation Opportunities with SBS Law
SBS Law is investigating potential fraud claims against MapLight Therapeutics, following significant stock drops. Investors may be eligible to join the probe.
third-news.com
August 3, 2026 at 6:34 AM
newsen.bsky.social
MapLight Therapeutics Initiates Initial Public Offering to Enhance Patient Care#USA#NASDAQ#San_Francisco#MapLight_Therapeutics#ML-007C-MA
MapLight Therapeutics Initiates Initial Public Offering to Enhance Patient Care
MapLight Therapeutics has filed for an initial public offering to boost its operations targeting CNS disorders, aiming to enhance patient care. This IPO marks a significant step in its mission.
third-news.com
October 6, 2025 at 8:13 PM
newsen.bsky.social
MapLight Therapeutics Secures $372.5 Million in Series D Financing Round to Drive CNS Innovations#United_States#Redwood_City#MapLight_Therapeutics#Alzheimer’s_Disease#Series_D_Funding
MapLight Therapeutics Secures $372.5 Million in Series D Financing Round to Drive CNS Innovations
MapLight Therapeutics has raised $372.5 million in Series D funding, co-led by Forbion and Goldman Sachs, to advance its CNS therapies and focus on schizophrenia and Alzheimer's.
third-news.com
July 28, 2025 at 12:11 PM
newsen.bsky.social
MapLight Therapeutics Launches Phase 2 Study for ML-007C-MA Targeting Schizophrenia Symptoms#United_States#Redwood_City#MapLight_Therapeutics#schizophrenia#ML-007C-MA
MapLight Therapeutics Launches Phase 2 Study for ML-007C-MA Targeting Schizophrenia Symptoms
MapLight Therapeutics has begun its Phase 2 trial of ML-007C-MA, a novel treatment for schizophrenia, focusing on efficacy, safety, and tolerability.
third-news.com
July 7, 2025 at 12:20 PM
newsen.bsky.social
MapLight Therapeutics Reports Phase 1 Trial Results for Innovative Treatment of Schizophrenia and Alzheimer's Psychosis#United_States#San_Francisco#Alzheimer's_Disease#MapLight_Therapeutics#schizophrenia
MapLight Therapeutics Reports Phase 1 Trial Results for Innovative Treatment of Schizophrenia and Alzheimer's Psychosis
MapLight Therapeutics reveals promising outcomes from the Phase 1 trial of ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis. Plans for Phase 2 are set for 2025.
third-news.com
December 2, 2024 at 1:16 PM